LianBio financial data

Symbol
LIANY on OTC
Industry
Pharmaceutical Preparations
Location
103 Carnegie Center Drive, Suite 309, Princeton, New Jersey
State of incorporation
Cayman Islands
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2023 - Nov 13, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.18K % -32%
Debt-to-equity 11.3 % -20.9%
Return On Equity -33.2 % -1.56%
Return On Assets -30.2 % -4.35%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 108M shares -0.27%
Common Stock, Shares, Outstanding 107M shares -1.09%
Entity Public Float 97.3M USD
Common Stock, Value, Issued 2K USD 0%
Weighted Average Number of Shares Outstanding, Basic 107M shares -1.1%
Weighted Average Number of Shares Outstanding, Diluted 107M shares -1.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 39.9M USD -29.8%
General and Administrative Expense 66.7M USD +8.75%
Operating Income (Loss) -107M USD +9.81%
Income Tax Expense (Benefit) 874K USD +9667%
Net Income (Loss) Attributable to Parent -88M USD +22.3%
Earnings Per Share, Basic -0.81 USD/shares -141%
Earnings Per Share, Diluted -0.81 USD/shares -141%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 103M USD +31.2%
Marketable Securities, Current 149M USD -36.1%
Cash, Cash Equivalents, and Short-term Investments 252M USD -19.1%
Assets, Current 258M USD -20.5%
Property, Plant and Equipment, Net 2.36M USD -24.6%
Operating Lease, Right-of-Use Asset 2.64M USD -39.4%
Other Assets, Noncurrent 20K USD -45.9%
Assets 263M USD -25.3%
Accounts Payable, Current 6.23M USD +209%
Accrued Liabilities, Current 15.9M USD -11.1%
Liabilities, Current 25.6M USD +16.3%
Operating Lease, Liability, Noncurrent 950K USD -68.5%
Other Liabilities, Noncurrent 213K USD +6.5%
Liabilities 26.8M USD -40.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -3.22M USD +16.2%
Retained Earnings (Accumulated Deficit) -540M USD -19.5%
Stockholders' Equity Attributable to Parent 202M USD -25.8%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 236M USD -23%
Liabilities and Equity 263M USD -25.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -17.6M USD -34.6%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 40.5M USD
Common Stock, Shares Authorized 2.92B shares 0%
Common Stock, Shares, Issued 107M shares -1.09%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 23.1M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 104M USD +4.64%
Deferred Tax Assets, Valuation Allowance 13.5M USD +41%
Deferred Tax Assets, Gross 14.4M USD +36.3%
Operating Lease, Liability 4.34M USD -10.2%
Depreciation 1.26M USD +35.4%
Payments to Acquire Property, Plant, and Equipment 19K USD -94.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -87.4M USD +25.4%
Lessee, Operating Lease, Liability, to be Paid 4.78M USD -14.6%
Property, Plant and Equipment, Gross 4.79M USD +10.1%
Operating Lease, Liability, Current 1.89M USD +8.17%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.09M USD +12.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.13M USD +40.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 441K USD -42.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 561K USD -69.3%
Deferred Tax Assets, Operating Loss Carryforwards 8.37M USD +31.7%
Deferred Tax Assets, Net of Valuation Allowance 860K USD -10.7%